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Abstract
The cardioprotective properties of new pharmaceuticals such as carvedilol
might be explained by enhanced mitochondrial protection. The aim of this
work was to determine the role of carvedilol in the protection of heart mito-
chondria from oxidative damage induced by hypoxanthine/xanthine oxi-
dase, a known source of oxidative stress in the vascular system. Carvedilol
reduced oxidative-stress-induced mitochondrial injury, as seen by the delay
in the loss of the mitochondrial transmembranar potential (), the decrease
in mitochondrial swelling, and the increase in mitochondrial calcium uptake.
Carvedilol improved the mitochondrial respiratory activity in state III and
offered an overall protection in the respiratory control and in the P/O ratios
in mitochondria under oxidative stress. The data indicated that carvedilol
was able to partly protect heart mitochondria from oxidative stress-induced
damage. Our results suggest that mitochondria can be important targets for
some cardioprotective pharmaceuticals.
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Introduction
Adenosine triphosphate (ATP) synthesis and the maintenance of mitochondrial
and cytosolic calcium homeostasis are two processes driven by the H+ electrochem-
ical gradient in heart mitochondria. Both processes are essential for myocardium
performance. The high-energy requirements of the cardiac muscle are almost exclu-
sively met by mitochondrial ATP production. A decrease in oxygen availability, as
in myocardial ischemia, could jeopardize mitochondrial function. This happens in
several heart dysfunctions that occur when the oxygen supply is not sufficient to
balance the rate of mitochondrial substrate oxidation. The role of mitochondria in
ischemic heart disease (for reviews, see refs. 1 and 2) is very important for design-
ing and studying novel cardiovascular drugs.
Hypoxia and reoxygenation are known to damage mitochondria in a process
associated with the so-called oxygen paradox, when the sudden availability of
